Genzyme believes that Synvisc-One will simplify osteoarthritis pain management and provide added patient convenience, while reducing the overall cost of therapy associated with multiple injections and offering a treatment option that will expand the benefits of viscosupplementation to a broader number of patients.
Ann Merrifield, president of Genzyme Biosurgery, the business unit of Genzyme, said: “The European approval of Synvisc-One is based on positive clinical data which demonstrated that combining three doses of Synvisc in a single treatment is safe and effective in providing pain relief for up to six months in patients with knee osteoarthritis. Delivering the benefits of Synvisc through one treatment rather than three will provide additional options for physicians and their patients to reduce the cost and burden of multiple injections.”